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Abstract 13 
Human diet has evolved to include not only nutritious foods but also health-promoting ones. 14 
Moreover, there is an increasing interest in replacing animal proteins as the main protein source. 15 
Insect based foods, e.g. Tenebrio molitor insect flour (TMIF), show potential as alternative 16 
protein sources for the human diet. This work aims to provide insights into the effect of TMIF 17 
upon the human gut microbiota and their metabolic end products by using an in vitro fecal 18 
model. Digested TMIF had a positive impact on gut microbiota, observed as an increase and/or 19 
upkeep of health promoting bacterial groups and by the production of SCFA (1.7 and 2.6 times 20 
higher acetate and propionate produced respectively than in the negative control at 48 h) and 21 
BCFA. A path is opened to acknowledge TMIF as a possible healthy nutritional source for 22 
human consumption, although in vivo trials would be necessary to confirm this. 23 
 24 
Keywords: in vitro digestion, anaerobic fecal fermentation model, insect flour, protein, gut 25 
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 27 
1. Introduction 28 
Changes in consumer awareness of global food sustainability are leading to consideration of 29 
alternative protein sources. Emerging studies indicate that insects could be a good source of 30 
protein, fiber, fatty acids and amino acids (Chen et al., 2009; Kouřimská and Adámková, 2016; 31 
Mlcek et al., 2014; Premalatha et al., 2011). As such, research into the benefits of insect 32 
consumption to the consumer is required. Currently, one of the most commercially used insects 33 
is the mealworm, Tenebrio molitor, which can be used and consumed in a flour form (Van Huis 34 
et al., 2013).  35 
Any non-digested portion of foods may provide an energy source for gut microbiota, residing 36 
mainly in the colon. This microbial community can be manipulated by diet and is known to 37 
have an impact on health. As such, an important perspective for the impact of food ingredients 38 
on the consumer can be obtained by investigating effects on host gut microbiota.  39 
The microbiota includes pathogenic and non-pathogenic microorganisms, as well as eukaryotic 40 
and prokaryotic cells and viruses. This microbial consortium plays a key role in the breakdown 41 
of dietary fiber, vitamin synthesis, nutrient cycling and energy metabolism. It also acts as a 42 
physical barrier to prevent pathogens from colonizing the GIT through competitive exclusion 43 
(Charaslertrangsi, 2014). In an adult, the dominant phyla include Firmicutes, Bacteroidetes, 44 
Proteobacteria and Actinobacteria (Charaslertrangsi, 2014; Moon et al., 2016; Thursby and 45 
Juge, 2017). These bacteria are involved in immunological activity, energy consumption, 46 
intestinal permeability, intestinal motility, and even effects in the enteric nervous system and 47 
brain activities (Barczynska et al., 2016; Bull and Plummer, 2014; Carabotti et al., 2015; Conlon 48 
and Bird, 2014; Derrien and van Hylckama Vlieg, 2015; Fung et al., 2017; Kim et al., 2016; 49 
Mayer et al., 2015; Powell et al., 2017). Some of these actions are driven by the ability of the 50 
microbiota to produce short-chain fatty acids (SCFA) (Brüssow and Parkinson, 2014; Louis et 51 
al., 2014; Ríos-Covián et al., 2016). As such, SCFA are important end products of microbial 52 
fermentation and their production is highly dependent on substrates reaching the large intestine.  53 
The understanding of host-microbiota-food component interactions is of major significance, 54 
and for that, simulation models can help elucidate this complex relationship. In vitro digestion 55 
models are used to assess and simulate physicochemical and physiological events of the 56 
digestive tract, allowing studies of structural changes, bioavailability and digestibility of foods 57 
when they arrive at the colon (Hur et al., 2011; Lee et al., 2016). As such, in vitro fermentation 58 
models are useful tools to screen substances, from dietary ingredients to pathogens and to assess 59 
how they alter or are altered by gastrointestinal environments and microbial populations 60 
(Verhoeckx et al., 2015). In vitro fermentation allows cultivation of complex intestinal 61 
microbiota, in controlled conditions, to study metabolism (Moon et al., 2016).  62 
 63 
The aim of this work was to evaluate the impact of an edible insect, Tenebrio molitor, on the 64 
human gut microbiota using an in-vitro digestion model.  This is a very novel study, only one 65 
similar previous study has been reported by Stull et al. 2018, where the impact of edible cricket 66 
consumption on human gut microbiota was investigated in an in vivo study. Two samples of 67 
the insect in flour form (TMIF) were investigated, digested and undigested and anaerobic fecal 68 
fermentation models were used. The evaluation of the impact of the samples on the gut 69 
microbiota was carried out based on measurements of bacterial composition and short fatty acid 70 
production during a time course. This enabled assessment of the potential of TMIF to impact 71 
on the microbial community and its metabolites. 72 
 73 
2. Material and methods 74 
2.1. Tenebrio molitor insect flour (TMIF) 75 
Tenebrio molitor insect flour (TMIF) was purchased from Insagri company, Málaga, Spain and 76 
kindly offered by Frulact company, Maia, Portugal. The composition and nutritional 77 
information of TMIF is shown in Table 1. 78 
 79 
2.2. TMIF sterilization 80 
To ensure TMIF was free of microorganisms, the sample was dried at 100 °C for 24 hours. 81 
 82 
2.3. In vitro gastrointestinal digestion protocol 83 
The TMIF digestion used an in vitro method mimicking in vivo conditions as described by Mills 84 
et al. (2008) with slight modifications. 20 g of TMIF were ground and dissolved in 50 mL 85 
distilled water and the mixture put in a stomacher (Seward, Worthing, UK) for 5 min. For the 86 
oral phase, 6.66 mg of α-amylase (A 4551, Sigma) in 2.08 mL of 0.001 M CaCl2 at pH 7.0 was 87 
added and incubated at 37 ºC for 30 min on a shaker. After this, 6 M HCl was used to lower the 88 
pH to 2.0. For the gastric phase, 0.9 g of pepsin (P 7000, Sigma) was dissolved in 8.33 mL of 89 
0.1 M HCl in a volumetric flask and this pepsin solution was added to the samples and incubated 90 
at 37 ºC for 2 h on a shaker. For the small intestinal phase, a pancreatin and bile solution was 91 
prepared. For that, 186.67 mg of pancreatin (P 8096, Sigma) and 1.17 g of bile (B 8631, Sigma) 92 
were dissolved in 41.67 mL of 0.5 M NaHCO3, and pH was adjusted to 7.0 with either 6 M of 93 
HCl or NaOH and incubated at 37ºC for 3 h on a shaker. The simulated digestion process of the 94 
TMIF also included a dialysis step to simulate the absorption in small intestine, in order to 95 
analyze the different behavior of bacteria present in the gut microbiota (Alegría et al., 2015; 96 
Verhoeckx et al., 2015). All samples were transferred to 100-500 Da molecular weight cut-off 97 
regenerated cellulose dialysis tubing (Spectra/Por® 6, Spectrum Europe, Netherlands) and a 98 
dialysis was performed against 1 M NaCl at 5 ºC to remove low molecular mass digestion 99 
products. After 15 h, the dialysis fluid was changed and performed for two additional hours. 100 
Afterwards, all samples were transferred to a freeze dryer (Armfield SB4 model, Ringwood, 101 
UK) in order to obtain a powder (digested TMIF) to be used for in vitro fecal fermentations. 102 
All chemicals were purchased from Sigma (St. Louis, USA). 103 
 104 
2.4. Gut microbiota simulation: Fecal fermentations 105 
2.4.1. Fecal microbiota  106 
Fecal samples were obtained fresh at the Department of Food and Nutritional Sciences, Reading 107 
from five healthy adult volunteers. The volunteers had normal omnivorous diets and had not 108 
ingested any antibiotics or other medicines known to affect the microbiota for at least 6 months 109 
prior to the study. Volunteers were 2 males and 3 females aged 22-37 years and were not regular 110 
consumers of prebiotics or probiotics. Samples were collected into clean containers and 111 
immediately placed in an anaerobic cabinet (nitrogen 80%, carbon dioxide 10%, hydrogen 112 
10%) (Don Whitley, UK) and used within 1 h of collection. A 10% (w/w) dilution in 0.1 M 113 
phosphate-buffered saline pH 7.4 (PBS) solution was prepared and homogenized using a 114 
stomacher (Serward, Worthing, UK) for 2 min at 460 paddle-beats per min. This produced a 115 
fecal slurry. 116 
 117 
2.4.2. Fecal batch-culture fermentation conditions 118 
Five independent fermentations were carried out using a sample from each donor. Sterile stirred 119 
batch culture fermentation vessels of 300 mL were set up and aseptically filled with 135 mL 120 
sterile basal nutrient medium (peptone water 2 g/L, yeast extract 2 g/L, NaCl 0.1 g/L, K2HPO4 121 
0.04 g/L, KH2PO4 0.04 g/L, MgSO4.7H2O 0.01 g/L, CaCl2.6H2O 0.01 g/L, NaHCO3 2 g/L, 122 
Tween 80 2 mL/L, hemin 0.05 g/L, vitamin K 10 µL/L, L-cysteine HCl 0.5 g/L, bile salts 0.5 123 
g/L and resazurin 4 mg/L) and gassed overnight with O2-free N2 with constant agitation. The 124 
temperature was kept at 37ºC. Four stirred pH-controlled batch fermenters were run in parallel: 125 
(1) 1% (w/v) digested TMIF was aseptically added; (2) 1% (w/v) undigested TMIF was 126 
aseptically added; (3) a positive control with 1% (w/v) FOS (a known prebiotic) from chicory 127 
root, purity: > 95%, degree of polymerization ranging from 2 to 8 (Megazyme, Bray, Ireland) 128 
and (4) a negative control which had no source of carbon added. Each vessel, with 135 mL of 129 
sterile basal nutrient medium was inoculated with 15 mL of fresh fecal slurry. A FerMac 260 130 
pH Controller (Electrolab Biotech Ltd., Tewkesbury, Gloucestershire, UK) was used, at 37 ºC, 131 
to maintain pH for each vessel between 6.7 and 6.9 (Sánchez-Patán et al., 2012).The batch 132 
cultures were conducted under anaerobic conditions at 37 ºC during 48 h, in which 5 mL 133 
samples were collected from each vessel at 0, 4, 8, 24 and 48 h for bacterial enumeration by 134 
fluorescence in situ hybridization (FISH), analysis of SCFA, BCFA and lactate by gas 135 
chromatography (GC) and quantification of ammonia with 53659-FluoroSelectTM Ammonia 136 
Kit (Sigma-Aldrich, Gillingham, Dorset, UK). All media and chemicals were purchased from 137 
Oxoid (Basingstoke, UK) and Sigma (St. Louis, USA). 138 
 139 
2.5. Bacterial enumeration by FISH-FCM 140 
Samples were analyzed by fluorescence in situ hybridization combined with flow cytometry 141 
(FISH-FCM) in order to determine differences in bacterial composition in the batch cultures. 142 
The FISH-FCM was performed according to the protocol used by Grimaldi et al. (2017) with 143 
slight modifications on volumes used on the permeabilization steps where, in this case, 150 µL 144 
of fixed batch culture samples were added to 500 µL 1x PBS.  145 
Table 2 shows the probes used (Eurofins Genomics, Ebersberg, Germany) in this protocol 146 
(Daims et al., 1999; Devereux et al., 1992; Franks et al., 1998; Harmsen et al., 1999; Harmsen 147 
et al., 2000; Hold et al., 2003; Langendijk et al., 1995; Manz et al., 1996; Walker et al., 2005; 148 
Wallner et al., 1993). Samples were stored at 4 ºC until flow cytometry (FCM) analysis by a 149 
BD Accuri TM C6 Cytometer (BD, Winnersh, Wokingham, UK). Numbers of specific and total 150 
bacteria were determined considering the dilution factor, calculated from different volumes 151 
used in the different steps of the preparation of the samples, and events/μL obtained from Non 152 
Eub338 and Eub338 I-II-III probes analyzed by FCM. 153 
 154 
2.6. Evaluation of organic acids production by GC 155 
GC analysis was performed to evaluate the production of organic acids by the gut microbiota,. 156 
From fecal batch cultures, 1 mL of sample of each vessel was transferred to a flat-bottomed 157 
glass tube and 50 µL of 2-ethylbutyric solution added to each tube. In the fume hood, 500 µL 158 
of concentrated HCl and 3 mL diethyl ether was added and vortexed. The tubes were centrifuged 159 
at 720 x g for 10 minutes at room temperature (18 ºC). The tubes went back again into the fume 160 
hood, where 400 µL upper layer of the tubes were transferred into GC-vials and 50 µL of N-161 
tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) added to each GC-vial. The 162 
vials were left at room temperature for at least 72 hours before conducting GC analysis. 163 
Production of the SCFA, BCFA (branched chain fatty acids) and lactate was determined by an 164 
Agilent/HP 6890 Gas Chromatograph (Hewlett Packard, UK) using an HP-5MS 30 m×0.25 mm 165 
column with a 0.25 μm coating (Crosslinked (5%-Phenyl)-methylpolysiloxane) (Hewlett 166 
Packard, UK). Temperatures of injector and detector were 275 °C, with the column programmed 167 
from 63 °C for initial time (0 minutes) to 190 °C at 15 °C min-1 and held at 190 °C for 3 min. 168 
Helium was the carrier gas (flow rate 1.7 mL/min; head pressure 133 KPa). A split ratio of 169 
100:1 was used.  Peaks were integrated using Agilent ChemStation software (Agilent 170 
Technologies, Oxford, UK) and organic acids content quantified by multiple-point internal 171 
standard method (12.5, 25, 50, 75 and 100 mM). Peak identity and internal response factors 172 
were determined using 0.1 mM calibration cocktail including acetate, propionate, isobutyrate, 173 
butyrate, isovalerate, valerate and lactate. 174 
 175 
2.7. Evaluation of ammonia production 176 
Quantification of ammonia present in the studied samples was performed with 53659-177 
FluoroSelectTM Ammonia Kit (Sigma-Aldrich, Gillingham, Dorset, UK) following the protocol 178 
that was provided by the kit. Briefly o-phthalaldehyde reagent was reacted with an amino acid 179 
solution and sulfite (reagent A) resulting in a color change in the presence of ammonia. As such 180 
a calibration curve of ammonia concentration was constructed alongside samples by recording 181 
fluorescence intensity at a wavelength of 360/460nm using a Tecan plate reader (Tecan Genios, 182 
Switzerland). 183 
 184 
2.8. Statistical analysis 185 
Statistical analysis of the results was carried out using IBM SPSS software (24.0.0.0, IBM, 186 
Chicago, USA). Normality of the distributions was evaluated using Shapiro-Wilk’s test. As the 187 
samples followed normal distribution, means were compared, considering a 95% confidence 188 
interval, using One-way ANOVA coupled with Tukey’s post-hoc test. The non-parametric 189 
Mann-Whitney test was used when the results did not follow a normal distribution. Differences 190 
between the total amino acids of digested and undigested TMIF were evaluated using an 191 
independent sample t-test as they proved to follow a normal distribution.  192 
 193 
3. Results and Discussion 194 
  195 
The impact of TMIF on the gut microbiota was assessed based on determination of bacterial 196 
composition by a molecular quantitative technique, FISH-FCM. Moreover, metabolic activity 197 
was determined based on the production of SCFA, BCFA and lactate; the amount of ammonia 198 
produced during fermentation was also determined. 199 
 200 
3.1. Analysis of the impact on bacterial composition 201 
Digested and undigested TMIF results for total bacteria were not significantly different and 202 
were very similar to those of the negative control. The digested TMIF sample should be richer 203 
in end-products (e.g. small peptides, amino acids) than the undigested TMIF upon simulated 204 
digestion. However, both products were subjected to a final dialysis step which should remove 205 
all small molecular products such as, free fatty acids, small peptides and amino acids. This 206 
would explain why no differences were observed in total bacteria between the two TMIF 207 
samples. 208 
Positive control (FOS) as expected, exhibited the most significant bacterial growth throughout 209 
the study period. In general, at all conditions, the concentration of different bacteria present in 210 
the fermentation vessels increased during the first 8 h of incubation. 211 
Results of bacterial composition are shown in Fig 1. Bifidobacterium spp. growth showed 212 
similar outcomes over incubation time for the digested and undigested TMIF. Bifidobacterium 213 
spp. on the positive control showed significant growth increase compared to the other 214 
conditions. Results obtained for Lactobacillus spp. showed a similar growth profile to those 215 
obtained for Bifidobacterium spp. Overall, better growth of Bifidobacterium spp. and 216 
Lactobacillus spp. was observed for samples with carbohydrates as substrate than with the two 217 
samples of TMIF which are predominantly protein. 218 
Growth of Bacteroidaceae and Prevotellaceae with TMIF samples (digested and undigested) 219 
were similar to the positive control. This may indicate, in this case, a positive impact of TMIF, 220 
as it partially matches the effect of FOS, in terms of bacteria upkeep, thus indicating that TMIF 221 
can be used as substrate by these bacteria. Bacteroides spp. possess strong peptidase activity 222 
and are associated with isovalerate and isobutyrate production (Scott et al., 2013; Zhao et al., 223 
2016). This means that Bacteroidaceae and Prevotellaceae, depending on the type of substrate, 224 
can utilize effectively both its saccharolytic and proteolytic pathways for growth.  225 
The growth of Atopobium cluster, has been reported to be increased by disaccharides, 226 
polysaccharides and long-chain inulin (Vinke et al., 2017). This seems to agree with results 227 
obtained with the positive control, where Atopobium cluster showed a significant increase at 8 228 
h and maintained these levels up to 48 h. In the presence of both forms of TMIF at 8 h, small 229 
and similar growth was observed. In the same samples, at 24 and 48 h, the results differed – the 230 
sample with the undigested form maintained the Atopobium cluster concentration level over 231 
such periods, while, in the digested form sample, a slight increase was observed, later followed 232 
by a decrease at 48 h. Atopobium cluster is relatively unresearched, and very few studies 233 
demonstrate a correlation between its presence and human health. Nevertheless, it has been 234 
reported that the presence of Atopobium correlated with beneficial effects in terms of 235 
cardiometabolic health (Vinke et al., 2017).   236 
Regarding the Clostridium coccoides / Eubacterium rectale group at 8 h, the sample with 237 
digested TMIF showed a significant decrease in cell numbers. In the case of undigested TMIF, 238 
positive and negative control no significant deviation was seen gin their growth profile (Fig 1). 239 
The Clostridium coccoides / Eubacterium rectale, is a group of anaerobic bacteria, well-known 240 
for butyrate production, as are Roseburia and F. prausnitzii, in the gut microbiota (Lopetuso et 241 
al., 2013). The Clostridium histolyticum group, is a clostridial group that possesses some 242 
pathogenic species such as Clostridium perfringens and Clostridium tetani. This group showed 243 
no significant deviations between samples at specific study times, except for positive control at 244 
24 and 48 h. Clostridia are proteolytic bacteria and some clostridia possess saccharolytic 245 
activity, preferably fermenting amino acids (Rowland et al., 2017; Scott et al., 2013).  246 
The Roseburia genera is also abundant in the intestinal microbiota, and it can produce both 247 
propionate and butyrate (Ríos-Covián et al., 2016). Roseburia spp. can grow in presence of 248 
carbohydrate, and some Roseburia spp. have FOS degradation genes or an inducible fructan 249 
utilization operon (Scott et al., 2013; Scott et al., 2015).  In this work, Roseburia showed slight 250 
growth in the presence of FOS at 8 and 24 h (Fig 1). At 48 h, a major decrease in Roseburia 251 
was observed, in the positive control, which may be explained by a decrease in FOS availability 252 
as it was being utilized during fermentation. In the presence of TMIF, a decrease was observed 253 
but the undigested form always maintained a higher concentration compared to the digested 254 
form.  255 
The Clostridium cluster IX belongs to the group of bacteria that mainly produce propionate in 256 
gut microbiota and use amino acids as main source of energy (Bernalier-Donadille, 2010; 257 
Tottey et al., 2017; Van den Abbeele et al., 2010). At 8 h, growth of this cluster was observed 258 
in the presence of TMIF, mostly in the undigested form sample. At 24 h the bacteria growth 259 
profile on FOS and TMIF samples were similar and at 48 h, a decrease was observed in all 260 
samples however, in the samples with undigested TMIF such a decrease was lower; 261 
nevertheless, these differences were not significant. In samples with TMIF, growth was 262 
expected, due to the presence of amino acids. As for the samples with FOS, growth was 263 
observed up to 24 h, which must be related with cross-feeding process, as these bacteria use 264 
lactate (previously produced by other bacteria) as substrate to produce propionate (Bernalier-265 
Donadille, 2010; Louis and Flint, 2017), which can be related to the lactate disappearance after 266 
8 h in the Fig 1.The cross feeding process may also explain the Clostridium histolyticum group 267 
growth in presence of FOS, up to the same study time (24 h).  268 
Faecalibacterium prausnitzii, a strictly anaerobic bacterium, is one of the most abundant 269 
species present in healthy human microbiota. It is one of the main butyrate producers (Conlon 270 
and Bird, 2014; Scott et al., 2015). In the presence of digested TMIF, bacteria growth showed 271 
a decrease over time. For the positive and negative control was also observed a decreasing 272 
growth profile over time. The sample with undigested TMIF, was the only one that showed, at 273 
8 h, slight growth of these bacteria. 274 
Desulfovibrionales and Desulfuromonales are only found in approximately fifty percent of 275 
humans (Rey et al., 2013). Predominant sulphate-reducing bacteria (SRB) in human colon are 276 
members of the genus Desulfovibrio. They can use hydrogen or organic compounds like lactate 277 
and formate to reduce sulphate to generate hydrogen sulphide (H2S), which has a toxic nature, 278 
that can have pathological consequences for the host (Conlon and Bird, 2014; Rowland et al., 279 
2017). Several studies identified SRB in the fecal microbiota of healthy adults and, despite 280 
being positively correlated with inflammation, the presence of H2S, has been attributed both to 281 
pro and anti-inflammatory signaling (Levine et al., 1998; Pitcher et al., 2000; Rey et al., 2013; 282 
Wallace et al., 2009). Lactate is also a favored co-substrate for these bacteria, forming acetate 283 
and sulphides. Desulfovibrio was reported to decrease in the presence of inulin, and studies 284 
showed that its lowered abundance can benefit health (Vinke et al., 2017). For this study, this 285 
group of bacteria was found in lower concentrations in the fecal samples of the donors, 286 
compared to other quantified groups. At 8 h, for all samples, there was a small increase of 287 
Desulfovibrionales and Desulfuromonales with no significant differences between the samples. 288 
After 8 h (24 and 48 h) a decline over time was observed. The small increase of these bacteria 289 
at 8 h may be correlated with the availability of lactate at that time (Fig 1). 290 
In this study, it was possible to see the effect of undigested and digested TMIF through 291 
modulation of gut bacterial populations. The most marked results were found on the growth of 292 
Bacteroidaceae and Prevotellaceae, which are bacteria related to proteolytic and saccharolytic 293 
activity conferring benefits to the host through their activity (e.g. propionate production). Such 294 
results make sense since TMIF is predominantly protein. It is important to highlight the fact 295 
that digested TMIF did not promote the growth of butyrate producers during the fermentation, 296 
such as Clostridium coccoides / Eubacterium rectale group, Roseburia subcluster and 297 
Faecalibacterium prausnitzii, while undigested TMIF promoted growth or maintained these 298 
bacteria. This study indicates an influence of TMIF on bacterial populations of the human gut 299 
microbiota however, in vivo studies must be carried out in order to evaluate the impact of such 300 
bacterial group variations on humans. 301 
 302 
3.2. Analysis of the impact on SCFA, BCFA and lactate production 303 
Acetate, propionate and butyrate are the most abundant SCFA existing in the colon, normally 304 
present in molar ratios ranging from 3:1:1 to 10:2:1 (Ríos-Covián et al., 2016; Rowland et al., 305 
2017; Scott et al., 2013; Tan et al., 2014). In this study SCFA and BCFA were found (Fig 2 and 306 
3). 307 
As a general overview, acetate, propionate and butyrate concentrations were significantly 308 
higher overtime for digested and undigested TMIF in comparison to the negative control (Fig 309 
2). In all cases, the positive control sample had significantly higher concentrations than the 310 
other samples.  311 
Butyrate is an important SCFA for human health. It provides an energy source for human 312 
colonocytes, possesses potential anti-cancer activities by inducing apoptosis of colon cancer 313 
cells and regulating gene expression, it nourishes intestinal cells and induces mucin production 314 
allowing changes in bacterial adhesion and improving tight-junction integrity (Barczynska et 315 
al., 2016; Ríos-Covián et al., 2016; Rowland et al., 2017). TMIF samples showed increased 316 
production of this SCFA (with higher production for the undigested form). Propionate acts as 317 
an energy source for epithelial cells, has a positive effect on the growth of hepatocytes, and also 318 
plays a role in gluconeogenesis in the liver (Barczynska et al., 2016; Ríos-Covián et al., 2016; 319 
Rowland et al., 2017). Propionate is also correlated with the promotion of satiety and with the 320 
reduction of cholesterol (Louis and Flint, 2017). This study showed an increased production of 321 
this SCFA over time and higher production in TMIF samples than in negative control (Fig 2). 322 
Acetate, which can be produced by bifidobacteria is an essential co-factor/metabolite for the 323 
growth of other bacteria, and even to inhibit enteropathogens (Ríos-Covián et al., 2016; 324 
Rowland et al., 2017). Acetate was also found to reduce the appetite through the interaction 325 
with the central nervous system (Ríos-Covián et al., 2016). Acetate is used by the human body 326 
in cholesterol metabolism and lipogenesis (Rowland et al., 2017). The present study supports 327 
the findings that acetate is one of the most abundant SCFA, as it shows high production values 328 
particularly after 8 hours (Fig 2). This was also observed in the TMIF samples where acetate 329 
concentration was higher than in the negative control sample, indicating that TMIF 330 
fermentation resulted in production of this acid. Although for the undigested and digested TMIF 331 
the acetate and propionate production were almost the same, the undigested sample had higher 332 
production of butyrate compared to the digested form. Overall these results are promising for 333 
the application of TMIF as a substitute of animal derived proteins in foods since acetate and 334 
propionate are both associated with the promotion of satiety. 335 
Lactate is also produced by bacteria, such as bifidobacteria and proteobacteria, despite not being 336 
a SCFA. In addition, lactate can also be used by butyrate and propionate producing bacteria, 337 
avoiding accumulation and metabolic acidosis (Flint et al., 2015; Ríos-Covián et al., 2016). 338 
Lactate production was higher in fermentation of FOS than in the other samples. No significant 339 
difference was found between the negative control and TMIF samples. An interesting result 340 
was observed in all samples as there was no lactate after 8 h (at 24 and 48 h). This is an expected 341 
result since, under normal physiological conditions, lactate does not accumulate in the colon 342 
because of its conversion into different organic acids through metabolic cross-feeding (Flint et 343 
al., 2015; Ríos-Covián et al., 2016; Rowland et al., 2017). 344 
TMIF samples produced higher concentration of BCFA than both the negative and positive 345 
controls particularly after 24 hours (Fig 3). The undigested TMIF sample was the one with the 346 
highest concentration of valerate, isobutyrate and isovalerate, especially at 24 and 48 h. 347 
Concentrations of these acids at 0 h and 4 h are null or very low for most trials, and significant 348 
levels appear mainly after 8 h. Moreover, digested TMIF was the only sample to show no 349 
valerate production. Little is known of the potential health benefit of valeric acids, how they 350 
are produced in the gut microbiota and what type of bacteria are these acids related to (Ríos-351 
Covián et al., 2016).  352 
These results showed a major impact of TMIF in the undigested form, especially over 8 h, on 353 
the production of the valerate, isobutyrate and isovalerate, which are normally present at low 354 
concentration in the human colon while acetate, propionate and butyrate are the most abundant 355 
(90-95%) (Huda-Faujan et al., 2010; Ríos-Covián et al., 2016). Isobutyrate and isovalerate are 356 
primarily produced from the protein degradation particularly, from branched amino acids 357 
fermentation and an increase in production of these acids maybe observed when the presence 358 
of carbohydrate is limited (Huda-Faujan et al., 2010). Fecal concentrations of BCFA are 359 
markers for bacterial protein fermentation, and not actual indicators of colonic health 360 
(Bernalier-Donadille, 2010; Scott et al., 2013; Verbeke et al., 2015).  361 
In summary, TMIF, in undigested or digested form, showed a positive impact on the production 362 
of SCFA and BCFA. The production of these by the gut microbiota may contribute to the host’s 363 
well-being.  364 
 365 
3.3. Analysis of the impact on ammonia production 366 
Considering the high protein level of TMIF, a small increase of ammonia may be expected with 367 
the fermentation of this substrate, as ammonia forms from the deamination of amino acids 368 
(Conlon and Bird, 2014; Davila et al., 2013; Ríos-Covián et al., 2016; Rowland et al., 2017; 369 
Scott et al., 2013). The presence of ammonia is an indicator of protein presence and degradation. 370 
Ammonia levels increased overtime in the presence of digested and undigested TMIF, in a 371 
similar concentration and pattern, except at 8 h (Fig 4). Bacteria degrade the protein present in 372 
the samples, thus becoming an indicator of protein degradation, occurring along the 373 
fermentation time.  374 
Fecal ammonia concentration in humans varies between 12 mM to 30 mM and increase with 375 
high intakes of protein (Scott et al., 2013). Higher levels can be considered negative for 376 
colonocytes, however, ammonia concentration levels obtained in this study seem to be within 377 
“safe levels” (up to 70 mM) (Leschelle et al., 2002; Tsujii et al. 1992).  378 
 379 
4. Conclusions 380 
According to the gut microbiota fecal in vitro model, TMIF had a positive impact as it promoted 381 
the growth of Bacteroidaceae and Prevotellaceae but not of Clostridium histolyticum group or 382 
Desulfovibrionales and Desulfuromonales. Also, TMIF showed a positive impact on the 383 
production of SCFA especially acetate and propionate and on the production of BCFA. The 384 
ammonia production in the TMIF samples was within concentration levels that are considered 385 
to have no cytotoxic effects. Therefore, TMIF shows potential as a protein source for human 386 
consumption due to its nutritional content and SCFA generating properties. Moreover, TMIF 387 
resulted in an increase in the production of acetate and propionate, these compounds have been 388 
associated with promotion of satiety (Louis and Flint, 2017; Ríos-Covián et al., 2016).This also 389 
opens the possibility for a protein enriched product without animal derived proteins and 390 
possibly additional functionalities. Human trials will be required to prove the additional 391 
functionalities. 392 
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List of tables:  606 
Table 1 - Nutritional composition of TMIF (per 100g), as provided by the manufacturer. 607 
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Component Concentration 
Total sugar <0.10 g 
Amino acids  5.4 g 
Cholesterol 0.002 mg 
Fiber 3.0 g 
Fat 39.4 g (saturated- 8.6g) 
Carbohydrates <0.10 g 
Humidity 7.5 g 
Protein 44.6 g 
Sodium 142 mg 
Energetic value 539 kcal  2242 kJ 
 
 628 
 629 
 630 
Table 2 - 16 rRNA oligonucleotide probes and hybridisation conditions used in the FISH 631 
analysis. *These probes were used together in equimolar concentration of 50 ng/µL. 632 
Probe 
name 
Specificity Sequence (5’- 3’) Reference 
Non 
Eub338 
--- ACTCCTACGGGAGGCAGC Wallner et al. (1993) 
Eub338 I-
II-III* 
Members of the domain 
Bacteria 
GCTGCCTCCCGTAGGAGT 
GCAGCCACCCGTAGGTGT 
GCTGCCACCCGTAGGTGT 
Daims et al. (1999)  
Bif164 Bifidobacterium spp.  CATCCGGCATTACCACCC Langendijk et al. 
(1995) 
Lab158 Lactobacillus spp./ 
Enterococcus spp. 
GGTATTAGCAYCTGTTTCCA Harmsen et al. (1999) 
Bac303 Most Bacteroidaceae and 
Prevotellaceae, some 
Porphyromonadaceae 
CCAATGTGGGGGACCTT Manz et al. (1996) 
Erec482 Most of the Clostridium 
coccoides/ Eubacterium 
rectale group (Clostridium 
cluster XIVa and XIVb) 
GCTTCTTAGTCARGTACCG Franks et al. (1998) 
Chis150 Most of the Clostridium 
histolyticum group 
(Clostridium cluster I and II) 
TTATGCGGTATTAATCTYCCTTT Franks et al. (1998) 
Rrec584 Roseburia subcluster  TCAGACTTGCCGYACCGC Walker et al. (2005) 
Ato291 Atopobium cluster GGTCGGTCTCTCAACCC Harmsen et al. (2000) 
Prop853 Clostridium cluster IX ATTGCGTTAACTCCGGCAC Walker et al. (2005) 
Fprau655 Fecalibacterium prausnitzii 
and related sequences 
CGCCTACCTCTGCACTAC Devereux et al. 
(1992) 
DSV687 Most Desulfovibrionales 
(excluding Lawsonia) and 
Desulfuromonales 
TACGGATTTCACTCCT Hold et al. (2003) 
 633 
 634 
 635 
 636 
 637 
Figure captions: 638 
Figure 1 - Bacterial populations (log (cells/mL), means ± SD) detected by FISH-FCM in Fecal 639 
samples (negative control (  ), positive control (  ), undigested TMIF (  ) and digested 640 
TMIF (  )). The used probes: I) total bacteria (Eub338), II) Bifidobacterium spp. (Bif164), 641 
III) Lactobacillus spp. (Lab158), IV) most Bacteroidaceae and Prevotellaceae (Bac303) and 642 
V) Atopobium cluster (Ato291), VI) Clostridium coccoides / Eubacterium rectale group 643 
(Erec482), VII) most of the Clostridium histolyticum group (Chis150), VIII) Roseburia 644 
subcluster (Rrec584), IX) Clostridium cluster IX (Prop853), X) Faecalibacterium prausnitzii 645 
(Fprau655) and XI) Desulfovibrionales and Desulfuromonales (DSV687). Different letters 646 
mark statistically significant (p<0.05) differences between samples at each sampling point. 647 
 648 
Figure 2 - Concentration (mM, means ± SD) of the SCFA and lactate produced along 649 
fermentation time in Fecal samples (negative control (  ), positive control (  ), undigested 650 
TMIF (  ) and digested TMIF (  )). Different letters mark statistically significant (p<0.05) 651 
differences between samples at each sampling point. 652 
 653 
Figure 3 - Concentration (mM, means ± SD) of BCFA and valerate produced along 654 
fermentation time in Fecal samples (negative control (  ), positive control (  ), undigested 655 
TMIF (  ) and digested TMIF (  )). Different letters mark statistically significant (p<0.05) 656 
differences between samples at each sampling point. 657 
 658 
Figure 4 - Concentration (mM, means ± SD) of ammonia produced along fermentation time in 659 
Fecal samples (negative control (  ), positive control (  ), undigested TMIF (  ) and 660 
digested TMIF (  )). Different letters mark statistically significant (p<0.05) differences 661 
between samples at each sampling point. 662 
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